<DOC>
	<DOC>NCT00261079</DOC>
	<brief_summary>Primary objective: - To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease Secondary objective: - To evaluate patient's satisfaction of Allegra treatment</brief_summary>
	<brief_title>Fexofenadine in Pruritic Skin Disease</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional. Main criteria are listed hereafter: All patients diagnosed with atopic dermatitis, contact dermatitis Other skin disease except atopic dermatitis, contact dermatitis. Subjects taken steroid within 4 weeks and antihistamine within 1 week before screening day. Pruritus localized only head and face Subjects with severe hepatic, renal, heart dysfunction. Subjects with history of alcohol and drug abuse. Pregnant and lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>